NCT06841926View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 20, 2025

Primary Completion Date

April 18, 2025

Study Completion Date

April 18, 2025

Conditions
Respiratory Viral Infection
Interventions
DRUG

ZX-7101A dry suspension

Test formulation (T) : ZX-7101A dry suspension Specification: 10 mg/ bag Dosage：40 mg (4 bags)、 once

OTHER

ZX-7101A tablet

Reference formulation (R): ZX-7101A tablet Specification: 40 mg/ tablet Dosage：40 mg (1 tablet)、 once

Trial Locations (1)

610041

West China Second University Hospital, Sichuan University and Children's Hospital Zhejiang University School of Medicine, Chengdu

Sponsors
All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY

NCT06841926 - Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males | Biotech Hunter | Biotech Hunter